Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating
Muhammad Ali Khalid
Tue, February 17, 2026 at 2:58 AM GMT+9 2 min read
In this article:
OLMA
-4.88%
Olema Pharmaceuticals (NASDAQ:OLMA) is one of the 17 biotechnology stocks with more than 50% upside.
On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA). She assigned a Buy rating to the stock with a $48 price target, which leads to more than 102% upside potential for investors.
Pressmaster/Shutterstock.com
Using a conservative approach, Prendergast has modeled peak sales for palazestrant at $3.1 billion in 2035. She also noted that endocrine therapy in ER+HER2 can be “a $20B+ global market opportunity with plenty of room for many big players.”
On January 7, Michael Yee of UBS also initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA), assigning a Buy rating and a $48 price target. He based his rating on a more favorable outlook for the biotech segment after what he described as a “rough period.” Yee expects greater investor confidence in the segment, which should drive better performance in 2026.
Olema Pharmaceuticals (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for women’s cancers. They commercialize next-gen breast cancer therapies, particularly targeting ER+/HER2- cancer. Its lead program is Palazestrant (OP-1250) to cure metastatic breast cancer, which is currently in Phase 3 clinical trials.
While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info